Ruti Aga's Six Years: The Ban Is for Three Failed Verifications, Not for a Steroid

Ten September. The start date of the ban, and the cleanest number in the file. Ruti Aga — Ethiopia, 32, marathon — suspended for six years. The substance at the centre of it is methylprednisolone, and it is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List, and out of competition its therapeutic use is entirely lawful. The positive sample came after she won a half marathon in China in March. That is the whole of it.

Which forces a pause. If the drug is legal, what exactly is six years for. The answer is not in the vial, it is in the paperwork. And until you look at how the sanction is built, you cannot tell whether this is a doping case or a document-verification case. The Athletics Integrity Unit's statement on Thursday contains two numbers that never made the headlines: two years for the presence violation, four years for tampering with the evidence. Two plus four is six. The arithmetic is clear. The question is which of the two did the damage.

Methylprednisolone deserves a proper explanation, because most of the coverage called it a steroid and that single word moved the gravity of the case to the wrong place. A glucocorticoid is an anti-inflammatory. An intra-articular injection for knee synovitis is as routine in distance runners as strapping is on a fast bowler's knee. The difference is that the Prohibited List restricts it in-competition only, by injection, oral or rectal route. An injection administered outside competition is not automatically an offence.

But the road-race testing window is brutal. In marathon and half marathon, the in-competition window opens at 23:59 the day before the race. An injection given three days earlier still becomes a case if residue is present on race day. So the technical question here is not whether she took a steroid. It is route and timing. That is precisely why the largest block of the sanction, four years, did not come from the substance at all.

I should set out my method, because most of the data in this story is unsourced. Only the AIU statement is quoted. The Chinese half marathon has no name, no time, no field strength; the year of the race is absent, and so is the year the ban expires. I will not make a performance claim on that. Where the file is blank, I leave it blank. My own old results sheet has 2:18:34 from Berlin 2026, second place, and 2:20:40 from Tokyo 2026, first — but those stay in the pending-verification column. I audited the feed for three nights before I trusted the number, and here the feed is half missing.

Three failed verifications, one prescription. According to the AIU, Aga cited a knee injury. The clinic that issued the prescription did not exist. The "doctor" who signed it was a family member with no medical registration. Questioned, that person said an old prescription pad from a former workplace had been used — and the clinic explicitly disowned the pad. Three separate verification points, three failures.

One detail matters more than the rest: the four-year tampering sanction came not from a document but from statements made in interview. A case that began with a sample ended with a conversation, and the language and translation conditions of AIU interviews with Ethiopian athletes remain a live point of contention. I record that without excusing it.

What is unambiguous is that the bulk of the punishment is procedural, not pharmacological. Two years for presence — the standard outcome for a specified substance absent proven intent — and four for tampering, the Code's standard. The addition tells you the panel rejected the no-significant-fault mitigation. Had the treatment been genuine and documented, a legitimate defence existed: route, timing, medical necessity. By forging the prescription she closed the one door that would have opened. That is the honest description of this case: the penalty is for how the drug was concealed, not for the drug.

The athlete had no TUE infrastructure around her. A properly managed runner does one of two things — obtains a therapeutic use exemption, or observes the route-specific washout. Neither happened. And when no genuine treatment record exists, people fabricate prescriptions. This is a medical-governance failure, not a character verdict. The knee injury may well have been real; the treatment may well have been real; the absence of correct paperwork belongs to the system around her, not to her alone.

The economics are not decoration here. China's label-race circuit is the between-Majors income tier for East African marathoners: decent appearance fees, dense fields, low race counts. It is also now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding inside the same races. This case is a product of that collision, not an aberration.

The career arithmetic is simple. Age 32, a six-year ban, a return at roughly 38. Ethiopian women's marathon depth is so extreme that a 2:18 performer is not automatically selectable; a 38-year-old with a doping record is effectively unselectable. The 2028 Olympic cycle is closed entirely, and backdating the ban to the provisional suspension is bookkeeping, not relief.

What survives is the 2026 Tokyo Marathon title and three World Marathon Majors podium finishes. The violation is anchored to a later March race; absent proof of earlier use, prior results are not automatically annulled. But the March result, its prize money and any ranking points accrued after it should be treated as gone. The statement does not define the disqualification scope, yet standard practice voids the competition at which the sample was collected.

The lesson for India is the one I keep filing. TUE literacy in Indian athletics is close to zero. A runner holding a railways or state-quota job takes a knee injection on a government hospital chit, unaware that a shot 72 hours before the start becomes a case if residue shows on race day. NADA has no shortage of tampering files, and nearly every one begins with a prescription written for genuine treatment but never properly documented.

Now the reading that makes me most suspicious. The easiest one is: doping caught, sanction delivered. It does not survive audit, because glucocorticoids have no proven endurance benefit. The substance that cost six years dulls pain; it does not expand a lung. The javelin model taught me that air is a variable nobody prices — here the variable is paper, and it was priced at six years.

The opposite reading — disproportionate enforcement against African road runners — does not fully hold either. The four-year tampering sanction comes from the same Code that applies to every nationality; there is no separate thumbscrew. And it would be wrong to treat a forged prescription as evidence of innocence. Correlation is not culpability: the knee injury may well have been real. But absent medical support and a fabricated prescription are two different things — the first is a system failure, the second is an athlete's. Collapsing them is the same error the media made by writing "steroid".

What to watch next. One circuit, one agent network, one informal medical support structure — more document-based cases are coming. The AIU's next front is not samples but prescriptions: registration numbers, whether the clinic exists, the date on the pad. And Indian athletics needs to spend on TUE literacy, or the next six-year ban will belong to somebody else for exactly the same reason. The question was never whether Ruti Aga took the medication. It is why nobody credentialed was there to write it down.